Enhancing Hypnotic Medication Discontinuation in Primary Care
A legfontosabb adatok
- Ki végzi
- National Jewish Health
- Hol
- Denver (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 250 fő, tervezett
- Kezdés
- 2025. jan. 1.
- Várható befejezés
- 2028. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- Digital Cognitive Behavioral Therapy
- Structured Medication Tapering
- A regiszteradat frissítve
- 2026. november 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with insomnia who have used sleeping pills for a long time and want to cut down or stop. It compares digital sleep therapy plus a guided dose reduction with the guided dose reduction alone.
- Életkor
- 18 years or older
- Nem
- All sexes
- A betegség stádiuma
- Insomnia disorder as defined by DSM-5, checked with a structured interview.
- Korábbi kezelés
- Use of a listed sleep medication (such as Zolpidem, Lorazepam, Trazodone, or Quetiapine ≤100mg) for ≥ 3 consecutive months and on ≥3 nights/week on average. People must want to reduce or stop it.
A részvétel fő kizáró okai
- Ever having a psychotic or bipolar disorder, a suicide attempt in the last 3 years, or current high suicide risk
- Unstable, untreated or terminal medical or mental health conditions, or a seizure disorder
- Alcohol or drug abuse in the past year, or more than 2 alcoholic drinks a day on 5 or more days a week
- Pregnancy, current use of corticosteroids, or a MoCA memory test score below 19
- Other sleep disorders such as narcolepsy or body clock disorders, or caregiving duties that disrupt sleep
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki nem vehet részt
- Appendix A: Eligible Medications
- Zolpidem (Ambien, Ambien CR)
- Lorazepam (Ativan)
- Clonazepam (Klonopin)
- Eszopiclone (Lunesta)
- Temazepam (Restoril)
- Zaleplon (Sonata)
- Alprazolam (Xanax)
- Diazepam (Valium)
- Trazodone (Desyrel)
- Doxepin (Silenor)
- Quetiapine (Seroquel), ≤100mg only
- Mirtazapine (Remeron)
- Hydroxyzine (Vistaril)
- Doxepin (Silenor)
- Prazepam (Centrax)
- Flurazepam (Dalmane)
- Quazepam (Doral)
- Triazolam (Halcion)
- Cholordiazepoxide (Librium)
- Halazepam (Paxipam)
- Estazolam (Prosom)
- Oxazepam (Serax)
- Clorazepate (Tranxene)
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- National Jewish HealthDenver, Egyesült ÁllamokContact: RJ JohnsonRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Many individuals with insomnia seek treatment in primary care settings, where they often receive prescription hypnotic medications as their first and sometimes only treatment. However, extended use of these medications can lead to reliance and increased health risks, such as falls and cognitive impairments. While evidence-based approaches like physician-supervised medication tapering exist, they're not widely available in primary care or other medical clinics.
A teljes eredeti leírásKevesebb
Most primary care providers are willing to explore non-drug treatments like cognitive behavioral therapy for insomnia (CBTI), but accessing such treatments can be challenging outside of specialized sleep centers. This gap between research and practice underscores the need for cost-effective interventions to manage insomnia and help patients reduce their reliance on hypnotics in primary care.
In response to this need, the project aims to conduct a large randomized trial comparing a combined digital CBT (dCBTI) and medication tapering intervention with medication tapering alone. We'll recruit 250 patients reliant on hypnotics across collaborating clinics and the general public . The main goal is to assess the effectiveness of dCBTI+SMT compared to SMT alone in reducing hypnotic use and improving insomnia symptoms.
Additionally, we'll evaluate factors affecting the adoption and implementation of these interventions at the patient, provider, and system levels. This information will inform future implementation strategies to disseminate effective treatments in primary care.
Furthermore, we'll gather data to identify which patients benefit most from dCBTI+SMT. Overall, this study will provide valuable insights into the feasibility, clinical utility, and acceptability of these interventions in managing insomnia and reducing reliance on hypnotic medications in medical settings. Ultimately, this project represents a crucial first step toward making accessible and cost-effective strategies available to improve the quality of life for millions of chronic users of sleep aids.
A vizsgálat 2 csoportja
- Digital cognitive behavioral therapy combined with structured medication taperingA vizsgált kezelés
dCBTI delivered in tandem with SMT during intervention phase.
Kezelés: Digital Cognitive Behavioral Therapy és Structured Medication Tapering
- Structured medication tapering aloneA vizsgált kezelés
Structured medication tapering delivered alone with general sleep hygiene information.
Kezelés: Structured Medication Tapering
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Enhancing Hypnotic Medication Discontinuation in Primary Care Through Supervised Medication Tapering and Digital Cognitive Behavioral Insomnia Therapy
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. november 12.